Medpace Holdings (MEDP) closed at $653.96 on October 22, 2026, down 1.3% from the previous close, on volume of 787,054 shares (30-day average 276,921).
Data as of October 22, 2026.
22-Oct-2026
Medpace lifts profitability in Q3 2026 as EBITDA margin reaches 24.0% and backlog tops $3.17B
Market Chameleon (Thu, 22-Oct 5:53 AM ET)
TipRanks (Thu, 22-Oct 9:20 AM ET)
Barclays Sticks to Its Hold Rating for Medpace Holdings (MEDP)
TipRanks (Thu, 22-Oct 5:39 AM ET)
Medpace raises 2026 EPS guidance range
Seeking Alpha News (Wed, 21-Oct 6:05 PM ET)
Medpace Holdings Announces Expanded $1 Billion Buyback Program
TipRanks (Wed, 21-Oct 5:46 PM ET)
Medpace GAAP EPS of $4.84 beats by $0.41, revenue of $716M beats by $1.56M
Seeking Alpha News (Wed, 21-Oct 4:19 PM ET)
Medpace Holdings, Inc. Reports Third Quarter 2026 Results
Business Wire (Wed, 21-Oct 4:15 PM ET)
Here are the major earnings after the close Wednesday
Seeking Alpha News (Wed, 21-Oct 10:00 AM ET)
Medpace Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 20-Oct 5:35 PM ET)
Medpace Holdings, Inc. to Report Third Quarter 2026 Financial Results on October 21, 2026
Business Wire (Tue, 22-Sep 4:05 PM ET)
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
Medpace Holdings trades on the NASDAQ stock market under the symbol MEDP.
As of October 22, 2026, MEDP stock price declined to $653.96 with 787,054 million shares trading.
MEDP has a beta of 0.53, meaning it tends to be less sensitive to market movements. MEDP has a correlation of 0.02 to the broad based SPY ETF.
MEDP has a market cap of $18.25 billion. This is considered a Large Cap stock.
Last quarter Medpace Holdings reported $716 million in Revenue and $4.84 earnings per share. This beat revenue expectation by $3 million and exceeded earnings estimates by $.38.
In the last 3 years, MEDP traded as high as $684.52 and as low as $227.21.
The top ETF exchange traded funds that MEDP belongs to (by Net Assets): IJH, VTI, VB, XMHQ, VBK.
MEDP has outperformed the market in the last year with a price return of +19.9% while the SPY ETF gained +14.9%. MEDP has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +23.0% and +8.2%, respectively, while the SPY returned +2.3% and -1.7%, respectively.
MEDP support price is $648.88 and resistance is $676.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MEDP shares will trade within this expected range on the day.
